- Clone:
- REA194 | CUB1
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC, MICS, IF, IHC Glossary
- Select a conjugate:
- Select a size:
Related products for CD318 (CDCP1) Antibody, anti-human, REAfinity™
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
Fluorescence microscopy image of CD318 (CDCP1) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CD318 (CDCP1)-PE (REA194, red) and counterstained with DRAQ5 (blue) as DNA stain.
Overlay histogram showing flow cytometric analysis of CD318 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD318-PE, clone (REA194). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Clone REA194 recognizes CD318, a type I transmembrane protein which is also known as CUB domain-containing protein 1 (CDCP1) or SIMA135. CD318 has an approximate molecular weight of 93 kDa and contains an extracellular domain with three regions with low homology to complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 (CUB) domains. CD318 has been suggested to be an interacting partner of Src family kinase and protein kinase Cδ. It has been shown that CD318 plays a role in cancer progression and the development of metastases. CD318 expression is found widely in normal tissues, whereas an aberrant overexpression is suggested to be associated with tumor cells.
Additional information: Clone REA194 displays negligible binding to Fc receptors.
CDCP1, SIMA135, TRASK
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?